Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has entered into an exclusive licensing agreement to commercialize Antares Pharma's topical oxybutynin gel product, as a treatment for overactive bladder (OAB), in the US and Canada.
Subscribe to our email newsletter
As per the terms of the agreement, Antares Pharma is entitled to receive milestone payments on achieving regulatory approval and certain sales level from Watson.
Antares Pharma is also eligible to receive escalating milestones upon product launch in the US and Canada from Watson.
Watson will be responsible for certain manufacturing start-up activities under the deal.
Watson Global Brands executive vice president Fred Wilkinson said the addition of Antares’ oxybutynin gel product will strategically enhance their overactive bladder product portfolio, potentially providing patients with the dosing flexibility of two strengths, allowing for dose titration, together with a convenient novel pump delivery system.